Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist. It is part of a dual antiplatelet therapy (DAPT) regimen.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** In combination with aspirin, for the reduction of thrombotic cardiovascular events in patients with ACS.
* **Myocardial Infarction (MI):** In patients with a history of MI, ticagrelor in combination with aspirin is indicated to reduce the rate of thrombotic cardiovascular events.
## Adult Dosing
* **ACS:**
* Loading Dose: 180 mg orally once.
* Maintenance Dose: 90 mg orally twice daily for at least 12 months, or until high bleeding risk or discontinuation due to other reasons. In certain patients, a lower dose of 60 mg twice daily may be considered after 12 months of DAPT.
* **History of MI:**
* Maintenance Dose: 60 mg orally twice daily. This indication is typically initiated after at least 12 months of DAPT with a P2Y12 inhibitor.
## Pediatric Dosing
Dosing in pediatric patients has not been established.
## Dose Adjustments
No dose adjustments are required for hepatic or renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracerebral hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Bleeding:** The most common and serious adverse effect. This includes spontaneous, traumatic, and gastrointestinal bleeding.
* **Dyspnea:** Transient, typically resolves with continued treatment.
* **Ventricular pauses:** Often asymptomatic.
* **Bradycardia.**
* **Hyperuricemia.**
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Strong inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **CYP3A4 Substrates:** Ticagrelor can increase the plasma concentration of CYP3A4 substrates (e.g., simvastatin, atorvastatin). Avoid high-dose statins.
* **Aspirin:** Concurrent use is generally indicated for ACS and post-MI patients.
* **Anticoagulants:** Increased risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
## Clinical Pearls
* Ticagrelor has a faster onset and offset of action compared to clopidogrel.
* Aspirin 75-100 mg daily is recommended for DAPT unless otherwise specified by local protocol.
* If a dose is missed, the patient should take the next dose at the scheduled time and not double the dose.
* Consider the patient's bleeding risk when initiating and continuing therapy.
*Disclaimer: This information is intended for clinical professionals. Always consult the most current prescribing information and institutional guidelines for complete details.*
